These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 19845042)

  • 41. Mouse intravenous challenge models and applications.
    MacCallum DM
    Methods Mol Biol; 2012; 845():499-509. PubMed ID: 22328398
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immune Protection against Lethal Fungal-Bacterial Intra-Abdominal Infections.
    Lilly EA; Ikeh M; Nash EE; Fidel PL; Noverr MC
    mBio; 2018 Jan; 9(1):. PubMed ID: 29339423
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Innate versus adaptive immunity in Candida albicans infection.
    Ashman RB; Farah CS; Wanasaengsakul S; Hu Y; Pang G; Clancy RL
    Immunol Cell Biol; 2004 Apr; 82(2):196-204. PubMed ID: 15061774
    [TBL] [Abstract][Full Text] [Related]  

  • 44. IL-33 Enhances Host Tolerance to Candida albicans Kidney Infections through Induction of IL-13 Production by CD4+ T Cells.
    Tran VG; Kim HJ; Kim J; Kang SW; Moon UJ; Cho HR; Kwon B
    J Immunol; 2015 May; 194(10):4871-9. PubMed ID: 25847973
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibiting the immunoproteasome exacerbates the pathogenesis of systemic Candida albicans infection in mice.
    Mundt S; Basler M; Buerger S; Engler H; Groettrup M
    Sci Rep; 2016 Jan; 6():19434. PubMed ID: 26776888
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Augmentation of host resistance to Candida albicans infection in ascites tumor-bearing mice.
    Okawa Y; Murata Y; Kobayashi M; Suzuki M; Suzuki S
    Microbiol Immunol; 1992; 36(5):517-21. PubMed ID: 1513264
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Candida albicans: pathogenesis, immunity and host defence.
    Ashman RB
    Res Immunol; 1998; 149(4-5):281-8; discussion 494-6. PubMed ID: 9720946
    [No Abstract]   [Full Text] [Related]  

  • 48. Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90.
    Matthews RC; Rigg G; Hodgetts S; Carter T; Chapman C; Gregory C; Illidge C; Burnie J
    Antimicrob Agents Chemother; 2003 Jul; 47(7):2208-16. PubMed ID: 12821470
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of adaptive immunity in the pathogenesis of Candida albicans keratitis.
    Zhang H; Chen H; Niu J; Wang Y; Xie L
    Invest Ophthalmol Vis Sci; 2009 Jun; 50(6):2653-9. PubMed ID: 19218608
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Candida albicans infection of Caenorhabditis elegans induces antifungal immune defenses.
    Pukkila-Worley R; Ausubel FM; Mylonakis E
    PLoS Pathog; 2011 Jun; 7(6):e1002074. PubMed ID: 21731485
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Organ-specific innate immune responses in a mouse model of invasive candidiasis.
    Lionakis MS; Lim JK; Lee CC; Murphy PM
    J Innate Immun; 2011; 3(2):180-99. PubMed ID: 21063074
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adaptive immune responses to Candida albicans infection.
    Richardson JP; Moyes DL
    Virulence; 2015; 6(4):327-37. PubMed ID: 25607781
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vivo immune responses to Candida albicans modified by treatment with recombinant murine gamma interferon.
    Garner RE; Kuruganti U; Czarniecki CW; Chiu HH; Domer JE
    Infect Immun; 1989 Jun; 57(6):1800-8. PubMed ID: 2498208
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Acute susceptibility of aged mice to infection with Candida albicans.
    Ashman RB; Papadimitriou JM; Fulurija A
    J Med Microbiol; 1999 Dec; 48(12):1095-1102. PubMed ID: 10591163
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice.
    Huang W; Na L; Fidel PL; Schwarzenberger P
    J Infect Dis; 2004 Aug; 190(3):624-31. PubMed ID: 15243941
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Investigation of the function of Candida albicans Als3 by heterologous expression in Candida glabrata.
    Fu Y; Phan QT; Luo G; Solis NV; Liu Y; Cormack BP; Edwards JE; Ibrahim AS; Filler SG
    Infect Immun; 2013 Jul; 81(7):2528-35. PubMed ID: 23630968
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interplay between Candida albicans and the mammalian innate host defense.
    Cheng SC; Joosten LA; Kullberg BJ; Netea MG
    Infect Immun; 2012 Apr; 80(4):1304-13. PubMed ID: 22252867
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antiarthritic effect of VIP in relation to the host resistance against Candida albicans infection.
    Zafirova Y; Yordanov M; Kalfin R
    Int Immunol; 2004 Aug; 16(8):1125-31. PubMed ID: 15237107
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Horizontal transmission of Candida albicans and evidence of a vaccine response in mice colonized with the fungus.
    Cutler JE; Corti M; Lambert P; Ferris M; Xin H
    PLoS One; 2011; 6(7):e22030. PubMed ID: 21818288
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neutrophil activation by Candida glabrata but not Candida albicans promotes fungal uptake by monocytes.
    Duggan S; Essig F; Hünniger K; Mokhtari Z; Bauer L; Lehnert T; Brandes S; Häder A; Jacobsen ID; Martin R; Figge MT; Kurzai O
    Cell Microbiol; 2015 Sep; 17(9):1259-76. PubMed ID: 25850517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.